Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leye He

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
Journal of Experimental & Clinical Cancer Research : CR|February 23, 2022
Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cellsLinglong Yin, Youhong Liu, Yuchong Peng, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 18, 2018
PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cellsLinglong Yin, Youhong Liu, Yuchong Peng, et al.
Molecular Therapy. Nucleic Acids|August 25, 2018
Molecular Recognition and In-Vitro-Targeted Inhibition of Renal Cell Carcinoma Using a DNA AptamerHui Zhang, Zhibo Wang, Lin Xie, et al.
Cancer Science|January 13, 2021
ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21Minhua Deng, Wensu Wei, Jinling Duan, et al.
Annals of Medicine|December 17, 2020
A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infectionYing Li, Yousheng Yin, Xiaomei Peng, et al.
Cancer Science|May 26, 2020
SLC12A5 interacts and enhances SOX18 activity to promote bladder urothelial carcinoma progression via upregulating MMP7Long Wang, Qun Zhang, Pei Wu, et al.
Journal of Nanobiotechnology|June 24, 2021
Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancerJianye Liu, Yi Zhang, Hongliang Zeng, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
Journal of Experimental & Clinical Cancer Research : CR|February 23, 2022
Correction to: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/. BRCA1 DNA damage repair complex in prostate cancer cellsLinglong Yin, Youhong Liu, Yuchong Peng, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 18, 2018
PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cellsLinglong Yin, Youhong Liu, Yuchong Peng, et al.
Molecular Therapy. Nucleic Acids|August 25, 2018
Molecular Recognition and In-Vitro-Targeted Inhibition of Renal Cell Carcinoma Using a DNA AptamerHui Zhang, Zhibo Wang, Lin Xie, et al.
Cancer Science|January 13, 2021
ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21Minhua Deng, Wensu Wei, Jinling Duan, et al.
Annals of Medicine|December 17, 2020
A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infectionYing Li, Yousheng Yin, Xiaomei Peng, et al.
Cancer Science|May 26, 2020
SLC12A5 interacts and enhances SOX18 activity to promote bladder urothelial carcinoma progression via upregulating MMP7Long Wang, Qun Zhang, Pei Wu, et al.
Journal of Nanobiotechnology|June 24, 2021
Fe-doped chrysotile nanotubes containing siRNAs to silence SPAG5 to treat bladder cancerJianye Liu, Yi Zhang, Hongliang Zeng, et al.
Pageof 6